Answers are grounded in this paper and cite their sources.
PURPOSE: To investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL). METHODS: In total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3-8 courses of chemotherapy. The expression of PD-L1 in tumor tissues from nine PTCL patients was also detected. RESULTS: sPD-L1 was higher in PTCL patients at diagnosis compared to healthy subjects (P < 0.0001). Patients in the intermediate/high-risk disease group had a higher level of sPD-L1 than patients in the low-risk group (P = 0.0003). Elevated sPD-L1 (≥176.30 pg/ml) was the only biomarker for PTCL that retain statistical significance in multivariate analysis. Patients in the low-risk group with sPD-L1 ≥ 176.30 pg/ml had an adverse prognosis. Histological analysis showed that the expression of PD-L1 in tissues was positively correlated with sPD-L1 levels in plasma (Spearman = 0.9177, P = 0.0013). CONCLUSIONS: sPD-L1 is a sensitive biomarker predicting clinical outcomes in PTCL.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: